Latest Breaking News On - Andy hsieh - Page 5 : comparemela.com

Exelixis (EXEL) Q4 2023 Earnings Call Transcript

EXEL earnings call for the period ending December 31, 2023.

Susan hubbardEtzer daroutPeter lawson barclaysWilliam blairAndy hsieh william blairAnish nikhanjMichael schmidt guggenheimJay olsonAkash tewari jefferiesChris sennerGregory renzaAndy hsiehYaron weberAsthika goonewardeneChristopher liu leerinkCheng li oppenheimer

Liver Disease Biotechs Stocks Crash on Eli Lilly s Mounjaro Data

New clinical trial results from El Lilly suggest its Type 2 diabetes and weight-loss drug, tirzepatide, could upend the incipient market for MASH treatments.

United statesEli lillyGeorge frey bloombergAndy hsiehJosh nathan kazisRaymond jamesEli lilly mounjaroWilliam blairSteven seedhouseDaniel skovronskyIntercept pharmaceuticalsMadrigal pharmaceuticalsDrug administrationNovo nordiskAkero therapeuticsViking therapeutics

Lantheus Holdings Shares Touch 52-Week Low After Executive Change

By Colin Kellaher Lantheus Holdings shares moved lower and hit a new 52-week low on Tuesday after the radiopharmaceutical company said its chairman and chief.

William blairAlexandra ramseyBrian markisonAndy hsiehMary anne heinoColin kellaherLantheus holdingsAvista capital partnersArticle normalMedical equipment suppliesTrusts funds financial vehiclesPrivate equityHealthcare life sciencesAlternative investmentsMedical diagnostic equipment suppliesFinancial services

Drugmakers turn to class of cancer drugs to fuel growth in 2024

Drugmakers turn to class of cancer drugs to fuel growth in 2024
beckershospitalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from beckershospitalreview.com Daily Mail and Mail on Sunday newspapers.

Andy hsiehAmbrx biopharmaWiliam blair companyWiliam blairMeta keywords drugmakersCancer drugsAntibody drug conjugatesTargeted therapy

Biotech and pharma companies are betting on a promising class of cancer drugs to drive growth

The JPMorgan Healthcare Conference was likely just the beginning of another year of heightened interest and investments in ADC cancer drugs.

New yorkUnited statesSan franciscoAlbert bourlaAndy hsiehDaina grayboschRobert davisWilliam blair hseihHansoh pharmaAmbrx biopharmaDaiichi sankyoWilliam blair companyHealthcare conferenceWilliam blairLeerink partnersChinese based hansoh pharma